Improve Your Commercial Growth Strategy with Custom-Tailored Intelligence

LEARN MORE

Precision Medicine Innovation Not Just a Numbers Game

by

We published a revision to our Precision Medicine Scorecard: Drug Company Edition last month. As John Audette rightfully notes, there are multiple factors in a pharmaceutical company’s contribution to precision medicines:

  • How many precision medicines a company currently markets;
  • The percentages of the company’s recent clinical trials that involve biomarkers;
  • The number of novel oncology drugs the company has in its pipeline;
  • The number of “proprietary” biomarkers the company is using in its clinical trials.

While we continue to highlight why biomarkers are critical to precision medicine we wanted to test the raw usage of biomarkers by the top 10 pharma against each other to further support John’s conclusions in the Scorecard.

We decided to leverage our new Workspace feature in BiomarkerBase to compare our ranking to general use of biomarkers by each of the top 10 pharma companies as compared against each other.  Our process was to simply compare each of the top 10 pharma against each other in biomarker usage in oncology.  We chose oncology because each top pharma company is well represented.

OncologyBiomarkersUsedInOncologyTop10.png

 

The top 5 pharmaceutical companies, by our Precision Medicine Scorecard, are using more biomarkers than anyone else.  However, second place Roche is more closely associated with seventh place Merck.  Third place AstraZeneca is below seventh place Merck.

More research is need to determine what practices are contributing to pharmaceutical company’s commercial success in precision medicine.  What do the biomarker practices look like at, for instance, Novartis?

 

Novartis Roche AstraZeneca Pfizer GSK Boehringer Ingelheim Merck Celgene Eisai J&J
Novartis 100 59 118 142 48 94 49 17 19
Roche 163 79 150 168 71 116 46 17 24
AstraZeneca 175 132 177 196 69 125 71 21 27
Pfizer 124 93 67 155 51 96 54 19 15
GSK 110 73 48 117 51 82 45 12 10
Boehringer Ingelheim 199 159 104 196 234 152 74 27 36
Merck 158 117 73 154 178 65 56 23 21
Celgene 230 164 136 229 258 104 173 31 45
Eisai 264 201 152 256 291 123 206 97 47
J&J 250 192 142 244 273 116 188 95 31
 Totals 1673 1231 860 1641 1895 698 1232 587 194 248
PageLines